<p>The group of scientists now found that the class of peptide may play an important role in reducing the risk of RSV-related asthma.</p><p>The newly discovered peptide named STAT6-IP may provide possible treatment of asthma infections related to the respiratory syncytial virus (RSV).Under research investigation, the team of researcher found that when newly discovered peptide named STAT6-IP delivered in the lungs of neonatal mice having first RSV exposure then it reduces the development of allergic-type lung inflammation and airway hyper responsiveness (&amp;quot;twitchy&amp;quot; airways) in the mice.</p><p>The research study recently published in the Journal of Leukocyte Biology with title: “STAT6 inhibitory peptide given during RSV infection of neonatal mice reduces exacerbated airway responses upon adult reinfection”</p>rnAccording to author,rn<p>&amp;quot;The incidence and severity of asthma and allergies have been increasing over the last 2-3 decades, affecting the general population in terms of both morbidity and cost. Our data suggest that exposure to STAT6-IP has the potential to modulate long-term responses to allergens and microbial antigens implicated in the development of asthma,&amp;quot; said Brian J. Ward, M.D., a researcher involved in the work and associate professor from McGill University Health Centre, Research Institute in Montreal, Quebec, Canada.</p><p>Note: for more information go through story source: <a href="http://www.faseb.org/">Federation of American Societies for Experimental Biology.</a></p><p>Journal References Bharat T. Srinivasa, Katherine H. Restori, Jichuan Shan, Louis Cyr, Li Xing, Soojin Lee, Brian J. Ward, Elizabeth D. Fixman. STAT6 inhibitory peptide given during RSV infection of neonatal mice reduces exacerbated airway responses upon adult reinfection. Journal of Leukocyte Biology, 2017; 101 (2): 519 DOI: 10.1189/jlb.4A0215-062RR</p>